Carcinotech

About:

Carcinotech is a MedTech company with expertise in manufacturing 3D printed living tumours for cancer research

Website: https://www.carcinotech.co.uk/

Twitter/X: carcinotech

Top Investors: Eos, Scottish Enterprise, Maven Capital Partners, TRICAPITAL, Old College Capital

Description:

Carcinotech is revolutionising cancer research by manufacturing 3D-printed micro-tumours using patient-derived biopsies, primary cells, immune cells, and cancer stem cells. Our advanced offering provides a platform for rapid, ethical, and accurate drug screening, pre-clinical, and personalised medicine testing. Carcinotech’s goal is to accelerate drug screening and enable the delivery of more effective cancer treatments to market. Using patient biopsies, tissue engineering, advanced robotic manufacturing, and quality control to produce highly predictive, assay-ready printed tumours at significant throughput. This provides our clients with a “clinical biopsy” quality model, using isolated patient-specific cells and representing donor-specific cancer heterogeneity. Our vision is to be at the forefront of cancer drug testing and provide personalised medicine testing to each individual suffering from cancer to better their chance of treatment and survival. Working with global partners, leading pharma companies, surgeons, pathologists, and clinicians Carcinotech is changing the face of oncology drug development by working to make this vision a reality.